Marrone Bio Achieves Excellent Climate Impact Score for Venerate® XC Bioinsecticide
November 17 2021 - 5:00PM
Marrone Bio Innovations, Inc. (NASDAQ: MBII) (MBI), an
international leader in sustainable bioprotection and plant health
solutions published today their independent climate impact product
assessment on Venerate® XC Bioinsecticide, scoring a 8.6 out of 10.
The analysis evaluated the life-cycle inputs and impacts of
Venerate XC per acre on the following: soil, aquatic and human
toxicity, ecosystem impact, harmful materials, greenhouse gas (GHG)
emissions and carbon return on investment (CROI).
“MBI is committed to providing farmers with the
most effective products that not only produce healthier, more
robust crops, but also meet the increasing demand for more
sustainably grown goods,” stated Kevin Helash, chief executive
officer for Marrone Bio Innovations. “This third party analysis
provides an excellent opportunity to showcase the value we bring to
all stakeholders.”
One of the key learnings from this product
analysis was the amount of electricity and steam required to
produce Venerate XC. The result was a decision to switch Marrone
Bio’s manufacturing facility in Bangor, Michigan to all-renewable
energy this fall, a move that reduced the amount of greenhouse gas
emissions the product generates by 32%.
A new element to this study was the addition of
a soil health metric; a key indicator of overall crop vigor and an
area of focus in present-day sustainable farming systems and
regenerative agricultural practices. The analysis showed Venerate
XC is non-toxic to earthworms and other soil-dwelling beneficial
organisms, and is readily biodegradable in the soil. The product’s
low toxicity is also demonstrated in its safety to humans and
aquatic life, key attributes that allowed Venerate XC to score an
8.6 out of 10 on climate impact.
Venerate XC Bioinsecticide, a top
revenue-generator for Marrone Bio, is a novel, broad spectrum
proprietary microbe (Burkholderia rinojensis strain A396) that is
active against a wide range of yield-robbing insects and mites. It
is approved for use in the U.S. and internationally on a wide range
of crops including almonds, grapes, strawberries, pome fruit and
leafy greens. Marrone Bio anticipates that this climate impact
assessment and pending regulatory approvals in a number of
countries, including Brazil, will allow Venerate XC to gain market
share globally and serve as a key contributor to revenue growth in
the coming years.
“The future of agriculture is dependent not only
on the best technology and most economical farming practices, but
also on our ability to preserve and protect the natural resources
in which our businesses rely,” added Keith Pitts, chief
sustainability officer for Marrone Bio Innovations. “Measuring our
environmental impact and understanding how it can improve our
manufacturing processes and product performance, while adding value
throughout the industry, is a key objective of commissioning these
third-party climate impact assessments. We want to lead the way in
providing innovative agriculture solutions that help farmers run a
more sustainable and profitable business while also becoming
suppliers of choice to the customers they serve.”
This is the second climate impact study Marrone
Bio has conducted with the help of Boundless Impact Research &
Analytics. The first product analysis was on the company’s BIOSt
Nematicide seed treatment that scored an impressive 9.8 out of 10,
reducing greenhouse gas (GHG) emissions by 85 percent in soybeans
and 87 percent in corn compared with conventional pesticides.
1. Research Methodology
OverviewBoundless researched the material, energy and
performance characteristics for Venerate XC Bioinsecticide based on
detailed information provided by MBI that describes the material
components and energy inputs. At the core of the methodology is a
life-cycle assessment (LCA) model for a kilogram of Venerate XC
Bioinsecticide. The functional unit (FU) for this LCA was a million
seeds treated with nematicide. Boundless employed the IPCC 2013
methodology.
About Marrone Bio
Innovations
Marrone Bio Innovations Inc. (NASDAQ: MBII)
is a growth-oriented agricultural company leading the movement to
environmentally sustainable farming practices through the
discovery, development and sale of innovative biological products
for crop protection, crop health and crop nutrition. Our portfolio
of 18 products helps customers operate more sustainably while
increasing their return on investment. The company’s commercial
products are sold globally and supported by a robust portfolio of
more than 500 issued and pending patents. Our end markets include
row crops; fruits and vegetables; trees, nuts and vines; and
greenhouse production. Marrone Bio’s research and development
program uses proprietary technologies to isolate and screen
naturally occurring microorganisms and plant extracts to create
new, environmentally sound solutions in agriculture.
Learn more about Marrone Bio Innovations at
www.marronebio.com. We also use our investor relations website,
https://investors.marronebio.com, as well as our corporate Twitter
account, @Marronebio, as means of disclosing material non-public
information, and encourage our investors and others to monitor and
review the information we make public in these locations. Follow us
on social media: Twitter, LinkedIn and Instagram.
Marrone Bio Innovations Forward Looking
StatementsThis press release contains forward-looking
statements within the meaning of the “safe harbor” provisions of
the Private Securities Litigation Reform Act of 1995.
Forward-looking statements involve substantial risks and
uncertainties. All statements, other than statements of historical
facts, included in this press release regarding strategy, future
operations and plans, including assumptions underlying such
statements, are forward-looking statements, and should not be
relied upon as representing the company’s views as of any
subsequent date. Examples of such statements include financial
guidance on Venerate XC and other statements regarding the
company’s future revenue growth, margins, operating expenses, and
other financial results; adoption of the company’s products; and
the potential benefits and value of the company’s products. Such
forward-looking statements are based on information available to
the company as of the date of this release and involve a number of
risks and uncertainties, some beyond the company’s control, that
could cause actual results to differ materially from those
anticipated by these forward-looking statements, including the
recent uncertainty in the global economy and industry-specific
economy caused by the COVID-19 pandemic, consumer, regulatory and
other factors affecting demand for the company’s products, any
difficulty in expanding the company’s sales and marketing
infrastructure or marketing the company’s products in global
markets, competition in the market for pest management products,
such as Venerate XC, lack of understanding of bio-based pest
management products by customers and growers, adverse actions by
distributors, manufacturers, regulatory agencies and other relevant
third parties and costs associated with any strategic acquisitions
or other business opportunities we elect to pursue. Additional
information that could lead to material changes in the company’s
performance is contained in its filings with the Securities and
Exchange Commission. The company is under no obligation to, and
expressly disclaims any responsibility to, update or alter
forward-looking statements contained in this release, whether as a
result of new information, future events or otherwise.
Marrone Bio Innovations Contact:Clyde
MontevirgenVice President of Business Development & Investor
RelationsTelephone: 530-750-2800info@marronebio.com
Marrone Bio Innovations (NASDAQ:MBII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Marrone Bio Innovations (NASDAQ:MBII)
Historical Stock Chart
From Jul 2023 to Jul 2024